Table 3.
Clinical end-points stratified by patient response according to mRECIST-CEUS
| Response according to mRECIST/CEUS | Overall survival (months) Estimate±SE (95%CI) | Time to progression (months) Estimate±SE (95%CI) | ||
|---|---|---|---|---|
|
|
|
|||
| Mean | Median | Mean | Median | |
| No Response | 11.02±1.33 | 8.00±3.44 | 10.97±1.48 | 10.00±1.53 |
| (8.42–13.62) | (1.26–14.74) | (8.06–13.87) | (7.01–12.99) | |
| Response | 37.19±3.34 | 43.00±7.55 | 24.67±3.11 | 30.00±6.50 |
| (30.65–43.74) | (28.20–57.80) | (18.57–30.77) | (17.27–42.73) | |
| Overall | 28.54±3.10 | 33.00±10.58 | 21.69±2.66 | 24.00±8.44 |
| (22.46–34.61) | (12.27–53.74) | (16.47–26.90) | (7.45–40.55) | |
CEUS, contrast-enhanced ultrasonography; CI, confidence interval; mRECIST, modified Response Evaluation Criteria In Solid Tumors; SE, standard error.